The Neurosurgery Drug market can be divided by type into four principal categories: small‑molecule agents, biologics, peptide‑based therapies, and gene‑therapy vectors. Small‑molecule drugs, administered orally or intravenously, dominate the market because of established manufacturing pipelines and lower regulatory barriers; they account for roughly 55 % of total sales, primarily supporting intra‑operative hemostasis and edema control. Biologics—monoclonal antibodies and recombinant proteins—contribute about 25 % and are increasingly used for targeted modulation of inflammatory cascades after craniotomy. Peptide‑based formulations, representing close to 12 % of revenue, offer rapid tissue penetration and are favored for neuroprotective adjuncts in tumor resection. Gene‑therapy vectors, still emerging, comprise the remaining 8 % and target long‑term expression of neuroregenerative factors. By isolating these type segments, analysts can attribute growth drivers such as pipeline innovation, reimbursement trends, and manufacturing scalability to specific portions of the overall Neurosurgery Drug segmentation. Furthermore, pricing differentials between oral small‑molecule agents and intravenously delivered biologics shape market share, while the regulatory pathway for gene‑therapy vectors imposes longer development cycles, influencing investment allocation.
